Table of Contents Author Guidelines Submit a Manuscript
Mediators of Inflammation
Volume 2012, Article ID 352807, 9 pages
http://dx.doi.org/10.1155/2012/352807
Research Article

Activation of Peroxisome Proliferator-Activated Receptor by Rosiglitazone Inhibits Lipopolysaccharide-Induced Release of High Mobility Group Box 1

1Department of Animal Biotechnology, Konkuk University, Seoul 143-701, Republic of Korea
2Department of Nursing, Semyung University, Jecheon 390-711, Republic of Korea
3Department of Applied Bioscience, College of Life Science, CHA University, Seongnam 463-712, Republic of Korea

Received 31 August 2012; Revised 27 November 2012; Accepted 29 November 2012

Academic Editor: Kuen-Jer Tsai

Copyright © 2012 Jung Seok Hwang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. Štros, “HMGB proteins: interactions with DNA and chromatin,” Biochimica et Biophysica Acta, vol. 1799, no. 1-2, pp. 101–113, 2010. View at Publisher · View at Google Scholar · View at Scopus
  2. U. Andersson and K. J. Tracey, “HMGB1 is a therapeutic target for sterile inflammation and infection,” Annual Review of Immunolgy, vol. 29, pp. 139–162, 2010. View at Google Scholar
  3. H. Wang, O. Bloom, M. Zhang et al., “HMG-1 as a late mediator of endotoxin lethality in mice,” Science, vol. 285, no. 5425, pp. 248–251, 1999. View at Publisher · View at Google Scholar · View at Scopus
  4. H. Yang, M. Ochani, J. Li et al., “Reversing established sepsis with antagonists of endogenous high-mobility group box 1,” Proceedings of the National Academy of Sciences of the United States of America, vol. 101, no. 1, pp. 296–301, 2004. View at Publisher · View at Google Scholar · View at Scopus
  5. J. Sundén-Cullberg, A. Norrby-Teglund, A. Rouhiainen et al., “Persistent elevation of high mobility group box-1 protein (HMGB1) in patients with severe sepsis and septic shock,” Critical Care Medicine, vol. 33, no. 3, pp. 564–573, 2005. View at Publisher · View at Google Scholar · View at Scopus
  6. L. Ulloa, M. Ochani, H. Yang et al., “Ethyl pyruvate prevents lethality in mice with established lethal sepsis and systemic inflammation,” Proceedings of the National Academy of Sciences of the United States of America, vol. 99, no. 19, pp. 12351–12356, 2002. View at Publisher · View at Google Scholar · View at Scopus
  7. G. Chen, J. Li, X. Qiang et al., “Suppression of HMGB1 release by stearoyl lysophosphatidylcholine: an additional mechanism for its therapeutic effects in experimental sepsis,” Journal of Lipid Research, vol. 46, no. 4, pp. 623–627, 2005. View at Publisher · View at Google Scholar · View at Scopus
  8. H. Wang, H. Liao, M. Ochani et al., “Cholinergic agonists inhibit HMGB1 release and improve survival in experimental sepsis,” Nature Medicine, vol. 10, no. 11, pp. 1216–1221, 2004. View at Publisher · View at Google Scholar · View at Scopus
  9. H. Wang, W. Li, J. Li et al., “The aqueous extract of a popular herbal nutrient supplement, Angelica sinensis, protects mice against lethal endotoxemia and sepsis,” Journal of Nutrition, vol. 136, no. 2, pp. 360–365, 2006. View at Google Scholar · View at Scopus
  10. I. Issemann and S. Green, “Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators,” Nature, vol. 347, no. 6294, pp. 645–650, 1990. View at Publisher · View at Google Scholar · View at Scopus
  11. D. J. Mangelsdorf, C. Thummel, M. Beato et al., “The nuclear receptor super-family: the second decade,” Cell, vol. 83, no. 6, pp. 835–839, 1995. View at Google Scholar · View at Scopus
  12. J. D. Tugwood, I. Issemann, R. G. Anderson, K. R. Bundell, W. L. McPheat, and S. Green, “The mouse peroxisome proliferator activated receptor recognizes a response element in the 5 flanking sequence of the rat acyl CoA oxidase gene,” EMBO Journal, vol. 11, no. 2, pp. 433–439, 1992. View at Google Scholar · View at Scopus
  13. G. S. Harmon, M. T. Lam, and C. K. Glass, “PPARs and lipid ligands in inflammation and metabolism,” Chemical Review, vol. 111, no. 10, pp. 6321–6340, 2011. View at Google Scholar
  14. L. A. Moraes, L. Piqueras, and D. Bishop-Bailey, “Peroxisome proliferator-activated receptors and inflammation,” Pharmacology and Therapeutics, vol. 110, no. 3, pp. 371–385, 2006. View at Publisher · View at Google Scholar · View at Scopus
  15. H. J. Kim, S. A. Ham, S. U. Kim et al., “Transforming growth factor-β1 is a molecular target for the peroxisome proliferator-activated receptor δ,” Circulation Research, vol. 102, no. 2, pp. 193–200, 2008. View at Publisher · View at Google Scholar · View at Scopus
  16. A. Chawla, Y. Barak, L. Nagy, D. Liao, P. Tontonoz, and R. M. Evans, “PPAR-γ dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation,” Nature Medicine, vol. 7, no. 1, pp. 48–52, 2001. View at Publisher · View at Google Scholar · View at Scopus
  17. H. J. Kim, I. S. Woo, E. S. Kang et al., “Identification of a truncated alternative splicing variant of human PPARγ1 that exhibits dominant negative activity,” Biochemical and Biophysical Research Communications, vol. 347, no. 3, pp. 698–706, 2006. View at Publisher · View at Google Scholar · View at Scopus
  18. K. J. Livak and T. D. Schmittgen, “Analysis of relative gene expression data using real-time quantitative PCR and the 2-ΔΔCT method,” Methods, vol. 25, no. 4, pp. 402–408, 2001. View at Publisher · View at Google Scholar · View at Scopus
  19. J. H. Yu, K. H. Kim, and H. Kim, “SOCS 3 and PPAR-γ ligands inhibit the expression of IL-6 and TGF-β1 by regulating JAK2/STAT3 signaling in pancreas,” International Journal of Biochemistry and Cell Biology, vol. 40, no. 4, pp. 677–688, 2008. View at Publisher · View at Google Scholar · View at Scopus
  20. C. Z. Wang, Y. Zhang, X. D. Li et al., “PPARγ agonist suppresses TLR4 expression and TNF-α production in LPS stimulated monocyte leukemia cells,” Cell Biochemistry and Biophysics, vol. 60, no. 3, pp. 167–172, 2011. View at Publisher · View at Google Scholar · View at Scopus
  21. L. M. Leesnitzer, D. J. Parks, R. K. Bledsoe et al., “Functional consequences of cysteine modification in the ligand binding sites of peroxisome proliferator activated receptors by GW9662,” Biochemistry, vol. 41, no. 21, pp. 6640–6650, 2002. View at Publisher · View at Google Scholar · View at Scopus
  22. M. Yu, H. Wang, A. Ding et al., “HMGB1 signals through toll-like receptor (TLR) 4 and TLR2,” Shock, vol. 26, no. 2, pp. 174–179, 2006. View at Publisher · View at Google Scholar · View at Scopus
  23. J. H. Kim, S. J. Kim, I. S. Lee et al., “Bacterial endotoxin induces the release of high mobility group box 1 via the IFN-β signaling pathway,” Journal of Immunology, vol. 182, no. 4, pp. 2458–2466, 2009. View at Publisher · View at Google Scholar · View at Scopus
  24. T. Haraguchi, K. Takasaki, T. Naito et al., “Cerebroprotective action of telmisartan by inhibition of macrophages/microglia expressing HMGB1 via a peroxisome proliferator-activated receptor γ-dependent mechanism,” Neuroscience Letters, vol. 464, no. 3, pp. 151–155, 2009. View at Publisher · View at Google Scholar · View at Scopus
  25. M. Gao, Z. Hu, Y. Zheng et al., “Peroxisome proliferator-activated receptor γ agonist troglitazone inhibits high mobility group box 1 expression in endothelial cells via suppressing transcriptional activity of nuclear factor κB and activator protein 1,” Shock, vol. 36, no. 3, pp. 228–234, 2011. View at Google Scholar
  26. Y. Sakamoto, K. Mashiko, H. Matsumoto, Y. Hara, N. Kutsukata, and Y. Yamamoto, “Relationship between effect of polymyxin B-immobilized fiber and high-mobility group box-1 protein in septic shock patients,” ASAIO Journal, vol. 53, no. 3, pp. 324–328, 2007. View at Publisher · View at Google Scholar · View at Scopus
  27. T. Ueno, T. Ikeda, K. Ikeda et al., “HMGB-1 as a useful prognostic biomarker in sepsis-induced organ failure in patients undergoing PMX-DHP,” Journal of Surgical Research, vol. 171, no. 1, pp. 183–190, 2011. View at Google Scholar
  28. K. Tsoyi, Y. M. Ha, Y. M. Kim et al., “Activation of PPAR-γ by carbon monoxide from CORM-2 leads to the inhibition of iNOS but not COX-2 expression in LPS-stimulated macrophages,” Inflammation, vol. 32, no. 6, pp. 364–371, 2009. View at Publisher · View at Google Scholar · View at Scopus
  29. C. Jiang, A. T. Ting, and B. Seed, “PPAR-γ agonists inhibit production of monocyte inflammatory cytokines,” Nature, vol. 391, no. 6662, pp. 82–86, 1998. View at Publisher · View at Google Scholar · View at Scopus
  30. H. Y. Ju and J. S. Shin, “Nucleocytoplasmic shuttling of HMGB1 is regulated by phosphorylation that redirects it toward secretion,” Journal of Immunology, vol. 177, no. 11, pp. 7889–7897, 2006. View at Google Scholar · View at Scopus
  31. T. Bonaldi, F. Talamo, P. Scaffidi et al., “Monocytic cells hyperacetylate chromatin protein HMGB1 to redirect it towards secretion,” EMBO Journal, vol. 22, no. 20, pp. 5551–5560, 2003. View at Publisher · View at Google Scholar · View at Scopus
  32. J. Evankovich, S. W. Cho, R. Zhang et al., “High mobility group box 1 release from hepatocytes during ischemia and reperfusion injury is mediated by decreased histone deacetylase activity,” Journal of Biological Chemistry, vol. 285, no. 51, pp. 39888–39897, 2010. View at Publisher · View at Google Scholar · View at Scopus